Che-Kai Tsao

459 total citations
10 papers, 338 citations indexed

About

Che-Kai Tsao is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Surgery. According to data from OpenAlex, Che-Kai Tsao has authored 10 papers receiving a total of 338 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 4 papers in Molecular Biology and 3 papers in Surgery. Recurrent topics in Che-Kai Tsao's work include Renal cell carcinoma treatment (4 papers), Renal and related cancers (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Che-Kai Tsao is often cited by papers focused on Renal cell carcinoma treatment (4 papers), Renal and related cancers (4 papers) and Bladder and Urothelial Cancer Treatments (3 papers). Che-Kai Tsao collaborates with scholars based in United States and Canada. Che-Kai Tsao's co-authors include Matthew D. Galsky, William Oh, Guru Sonpavde, Noah M. Hahn, Menggang Yu, Ziyue Liu, Toni K. Choueiri, Tracy Proverbs‐Singh, Sophia Chiu and Alexander Small and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and The Oncologist.

In The Last Decade

Che-Kai Tsao

10 papers receiving 333 citations

Peers

Che-Kai Tsao

PRM

IM

SURGE

ONCOL

MB

Jean Chidiac France

Ilias Athanasiadis Greece

David Rossi Italy

Diana Kassab‐Chahmi France

Julia Calzas Spain

Elaine McCartney United Kingdom

Alberto Agazzi Italy

Lee Chun Park South Korea

M. Martín Jiménez Spain

Yu Jung Kim South Korea

Jean Chidiac France

Che-Kai Tsao

59 ×0.4

PRM

172 ×1.4

IM

62 ×0.7

SURGE

72 ×0.8

ONCOL

63 ×0.8

MB

Citations per year, relative to Che-Kai Tsao Che-Kai Tsao (= 1×) peers Jean Chidiac

Countries citing papers authored by Che-Kai Tsao

Since Specialization

Citations

This map shows the geographic impact of Che-Kai Tsao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Che-Kai Tsao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Che-Kai Tsao more than expected).

Fields of papers citing papers by Che-Kai Tsao

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Che-Kai Tsao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Che-Kai Tsao. The network helps show where Che-Kai Tsao may publish in the future.

Co-authorship network of co-authors of Che-Kai Tsao

This figure shows the co-authorship network connecting the top 25 collaborators of Che-Kai Tsao. A scholar is included among the top collaborators of Che-Kai Tsao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Che-Kai Tsao. Che-Kai Tsao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

1.

Tsao, Che-Kai, Matthew D. Galsky, John P. Sfakianos, et al.. (2024). Tumor Characteristics Associated With Preoperatively Detectable Tumor-Informed Circulating Tumor DNA in Patients With Renal Masses Suspicious for Renal Cell Carcinoma. JCO Precision Oncology. 8(8). e2400281–e2400281. 5 indexed citations

2.

Galsky, Matthew D., Noah M. Hahn, Bryan Wong, et al.. (2015). Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma. Cancer Chemotherapy and Pharmacology. 76(6). 1259–1265. 6 indexed citations

3.

Agarwal, Neeraj, Andrea B. Apolo, Che-Kai Tsao, et al.. (2014). Phase Ib/II Trial of Gemcitabine, Cisplatin, and Lenalidomide as First-Line Therapy in Patients With Metastatic Urothelial Carcinoma. The Oncologist. 19(9). 915–916. 6 indexed citations

4.

Goyal, Jatinder, Gregory R. Pond, Matthew D. Galsky, et al.. (2013). Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 32(1). 36.e27–36.e34. 15 indexed citations

5.

Small, Alexander, Che-Kai Tsao, Erin Moshier, et al.. (2012). Trends and variations in utilization of nephron-sparing procedures for stage I kidney cancer in the United States. World Journal of Urology. 31(5). 1211–1217. 15 indexed citations

6.

Tsao, Che-Kai, Alexander Small, Erin Moshier, et al.. (2012). Trends in the Use of Cytoreductive Nephrectomy in the United States. Clinical Genitourinary Cancer. 10(3). 159–163. 20 indexed citations

7.

Tsao, Che-Kai, Alexander Small, Matthew D. Galsky, & William Oh. (2012). Overcoming castration resistance in prostate cancer. Current Opinion in Urology. 22(3). 167–174. 12 indexed citations

8.

Tsao, Che-Kai, Alexander Small, Max Kates, et al.. (2012). Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World Journal of Urology. 31(6). 1535–1539. 49 indexed citations

9.

Proverbs‐Singh, Tracy, Sophia Chiu, Ziyue Liu, et al.. (2012). Arterial Thromboembolism in Cancer Patients Treated With Cisplatin: A Systematic Review and Meta-analysis. JNCI Journal of the National Cancer Institute. 104(23). 1837–1840. 35 indexed citations

10.

Liu, Ziyue, Sophia Chiu, Tracy Proverbs‐Singh, et al.. (2012). Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis. Journal of Clinical Oncology. 30(35). 4416–4426. 175 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact